Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT05502237. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.
Study identification
- NCT ID
- NCT05502237
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,021 participants
Conditions and interventions
Conditions
Interventions
- Zimberelimab Drug
- Domvanalimab Drug
- Pembrolizumab Drug
- Carboplatin Drug
- Cisplatin Drug
- Paclitaxel Drug
- Nab-paclitaxel Drug
- Pemetrexed Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 12, 2022 (Actual)
- Primary completion
- Jun 2028 (Estimated)
- Completion
- Jan 2029 (Estimated)
- Last update posted
- Jan 30, 2026
2022 – 2029
United States locations
- U.S. sites
- 11
- U.S. states
- 11
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Innovative Clinical Research Institute | Whittier | California | 90606 | — |
| George Washington Medical Faculty Associates | Washington D.C. | District of Columbia | 20052 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Illinois Cancer Care | Peoria | Illinois | 61615 | — |
| Messino Cancer Centers | Asheville | North Carolina | 28806 | — |
| Oncology Hematology Care, Inc. | Cincinnati | Ohio | 45242 | — |
| Hematology & Oncology Associates | Eugene | Oregon | 97401 | — |
| AHN Allegheny General Hospital | Pittsburgh | Pennsylvania | 15212 | — |
| Texas Oncology - Austin | Austin | Texas | 78745 | — |
| Oncology and Hematology Associates of Southwest Virginia, Inc | Blacksburg | Virginia | 24060 | — |
| Northwest Cancer Specialists, PC | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 175 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05502237, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 30, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05502237 live on ClinicalTrials.gov.